Clinical trials: Schizo Affective Disorder
Schizophrenia, Schizoaffective Disorders
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
This study involves people with schizophrenia or schizoaffective disorder, who are currently taking antipsychotic medications. Some antipsychotic medications may cause an increase in cholesterol levels, which may lead to…
- Conditions
- Schizophrenia, Schizoaffective Disorders, Schizophreniform Disorders
- Trial name
- NCT01082588
- Testing
- Pravastatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Psychotic Disorders
Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
This study will assess the effectiveness of pimozide in enhancing the effects of clozapine in the treatment of schizophrenia.
- Trial name
- NCT00158223
- Testing
- Pimozide
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Schizophrenia, Schizoaffective Disorder
Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder
The proposed study is a 4-site, 12-week, novel, feasibility, investigation of patients who have co-occurring diagnoses of schizophrenia and current substance use disorder (alcohol, cocaine, heroin, or cannabis).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Substance Use Disorders
- Trial name
- NCT03526354
- Testing
- Brexpiprazole, Treatment as Usual
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Massachusetts, Worcester
Schizophrenia, Schizo Affective Disorder
Models of Auditory Hallucination
The purpose of this study is to address the shortcoming in clinical hallucination research by causally manipulating the neural loci of conditioned hallucination task behavior in-person in patients with psychosis using…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Auditory Hallucination
- Trial name
- NCT04210557
- Testing
- Transcranial Magnetic Stimulation (TMS)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Yale University
Schizophrenia
An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to evaluate the efficacy and safety of long acting injectable (LAI) risperidone and oral risperidone treatment on participants with schizophrenia (psychiatric disorder with symptoms of emotional…
- Trial name
- NCT00992407
- Testing
- Risperidone long acting injectables, Risperidone tablets
- Where
- South Korea
- Volunteers
- 75 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia, Schizoaffective Disorder
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.
- Trial name
- SWITCHCore (NCT01143077)
- Testing
- Lurasidone HCl
- Where
- 27 sites in United States
- Volunteers
- 244 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
The purpose of this study is to evaluate the effectiveness, safety and tolerability of risperidone long-acting injection (LAI) versus oral antipsychotics in participants with recent onset psychosis (abnormal thinking and/or…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
- Trial name
- NCT00246259
- Testing
- Risperidone long-acting injection (LAI), Oral Antipsychotic
- Where
- 11 sites in Canada
- Volunteers
- 77 people
- Sponsor
- Janssen-Ortho Inc., Canada
Schizophrenia, Schizoaffective Disorder
Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia
Schizophrenia is marked by problems in attention, memory and problem solving. These deficits predict long-term functional outcome such as the ability to live independently and maintain employment, but they are not ameliorated by…
- Trial name
- NCT02069392
- Testing
- Cognitive remediation training, Nicotine polacrilex lozenge
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia.
- Trial name
- NCT00320671
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
The purpose of this study was to determine whether patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who also have metabolic syndrome have a larger decrease in fasting non-high density lipoprotein…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
- Trial name
- NCT00857818
- Testing
- Aripiprazole, Oanzapine, risperidone, or quetiapine
- Where
- 14 sites in Canada
- Volunteers
- 64 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychotic Disorders, Schizoaffective Disorder
Functional Rehabilitation of Older Patients With Schizophrenia
The primary purpose of this project is to evaluate the efficacy of a group therapy intervention, cognitive behavioral social skills training (CBSST), that teaches social functioning skills and cognitive-behavioral compensatory…
- Conditions
- Psychotic Disorders, Schizoaffective Disorder, Schizophrenia
- Trial name
- NCT00237796
- Testing
- Cognitive Behavioral Social Skills Training (CBSST), Goal Focused Supportive Contact (GFSC)
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- US Department of Veterans Affairs
Bipolar Disorder, Schizophrenia
Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders
Persons with serious mental illness (SMI) are at increased risk of cardiovascular disease (CVD). The goals of this study are to test a treatment, Life Goals Collaborative Care to help promote health behavior change and improve…
- Conditions
- Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder
- Trial name
- NCT01487668
- Testing
- Life Goals Collaborative Care
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Negative Type; Schizophrenic
Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia
The main purpose of this study is to learn how transcranial magnetic stimulation (TMS) helps improve negative symptoms of schizophrenia.
- Conditions
- Schizophrenia, Negative Type; Schizophrenic, Schizo Affective Disorder
- Trial name
- NCT03648268
- Testing
- repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia, Psychotic Disorder NOS
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
The primary objective of this study is to determine if NAC, added to existing antipsychotic treatment, is superior to placebo for cortical erosion in patients with early stage psychosis.
- Conditions
- Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
- Trial name
- Breier-Stanley (NCT01339858)
- Testing
- N-Acetyl Cysteine, sugar pill
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Indiana University
Schizophrenia, Schizoaffective Disorder
Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia
These studies look to conduct efficient pilot testing of a novel intervention strategy for chronic psychotic disorders - Pharmacologic Augmentation of Cognitive Therapy (PACT) - via an experimental medicine approach.
- Trial name
- NCT04414930
- Testing
- d-amphetamine
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of California, San Diego
Schizophrenia, Bipolar Disorder
Restoration of Cognitive Function With TDCS and Training in Serious Mental Illness
Development of interventions that can effectively target and remediate the cognitive and functional impairment associated with serious mental illness is a treatment priority.
- Conditions
- Schizophrenia, Bipolar Disorder, Schizo Affective Disorder
- Trial name
- NCT03208036
- Testing
- TDCS, Cognitive Remediation, Bridging Group
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Theta Burst Stimulation for Schizophrenia
Purpose and objective Schizophrenia is a chronic debilitating illness with cognitive deficits that cause serious impairment in psychosocial recovery and with few treatments to remediate these deficits.
- Trial name
- NCT03288779
- Testing
- Theta Burst Stimulation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Schizophrenia, Schizoaffective Disorder
STimulation to Improve Auditory haLLucinations
Investigating the effects of non-invasive transcranial current stimulation as a treatment for auditory hallucinations in patients with schizophrenia.
- Trial name
- STILL 2 (NCT02360228)
- Testing
- tACS (alpha), tDCS
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizoaffective Disorder, Schizophrenia
Motivational Interviewing to Improve Work Outcomes in Schizophrenia
Many persons with schizophrenia have difficulty getting and keeping a job. This study is designed to compare the benefits of four sessions of motivational interviewing or illness education in increasing employment rates accruing…
- Trial name
- NCT00261716
- Testing
- IPS, IE, VOMI
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing…
- Trial name
- NCT00237809
- Testing
- D-serine, Cognitive Retraining (CRT)
- Where
- 2 sites in United States
- Volunteers
- 104 people
- Sponsor
- Yale University